Counterfeit drugs plague Tanzania

26 January 2009

Although knock-off merchandise of almost any kind is available in Tanzania's markets, the most dangerous counterfeits are the imitation  medicines sold to unwitting consumers, reports AllAfrica.com. In  Tanzania and across the developing world, the business of fake drugs is  booming. The World Health Organization has estimated that, in the  developing countries of Africa, and in parts of Asia and Latin America,  up to 30% of medicines on the market are counterfeit.

Edith Ngirwamungu, president of the Medical Association of Tanzania,  said: "the consequences of this business are really immense. Take, for  example, a person with severe malaria: if he or she cannot access the  genuine drug, then it means they may die." She added that inefficacy of  counterfeit pharmaceuticals also made some Tanzanians lose confidence  in crucial medicines, such as antiretrovirals for people living with  HIV/AIDS.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight